Kepler-452b revolves around a sun much like our own.
The Ontario Superior Court of Justice rules that the Canadian Broadcasting Company did not commit libel in its documentary series on fraud allegations against Ranjit Chandra.
Financial Growing Pains of a Biotech Illustrations by Tomasz Walenta Large risks and high costs dominate the financial life cycle of a biotechnology company, but the potential payoffs are huge. By Sam Hall and Alastair J.J. Wood Illustrations by Tomasz Walenta Related Articles 2, legacy pharmaceutical companies typically pay biotech licensors a midpoint value of ~$220 million for Phase III drugs, compared with only ~$65 million for drugs in Phase I clinical
August 1, 2008|
September 9, 2008